Literature DB >> 1282107

Cyclosporine is angiostatic.

K Norrby1.   

Abstract

The systemic effect of the immunosuppressive drug cyclosporine (CS) on formation of new blood vessels was studied quantitatively in rats using the mesenteric-window assay. Angiogenesis was induced by i.p. injection of saline. CS at a s.c. dose of 4 mg/kg/day, which is in the range used clinically, suppressed angiogenesis (inhibiting branching or tortuosity more than spatial expansion), and appeared to be non-toxic. This is the first report on an apparently selective angiostatic effect of CS. The finding is likely to have implications for the clinical use of CS, not only in certain types of organ transplantation but possibly also in psoriasis and other angiogenesis-dependent diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282107     DOI: 10.1007/BF01948007

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  47 in total

1.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

2.  Cyclosporin for psoriasis.

Authors:  J I Harper; A C Keat; R C Staughton
Journal:  Lancet       Date:  1984-10-27       Impact factor: 79.321

3.  Cyclosporin A stimulates proliferation of the liver cells after partial hepatectomy in rats.

Authors:  Y I Kim; R Y Calne; N Nagasue
Journal:  Surg Gynecol Obstet       Date:  1988-04

4.  Reversibility of cyclosporine-induced hypoandrogenism in rats.

Authors:  S C Sikka; M A Koyle; R S Swerdloff; J Rajfer
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

5.  Quantitative angiogenesis in spreads of intact rat mesenteric windows.

Authors:  K Norrby; A Jakobsson; J Sörbo
Journal:  Microvasc Res       Date:  1990-05       Impact factor: 3.514

6.  Cyclosporin A inhibits rat mast cell activation.

Authors:  L Dráberová
Journal:  Eur J Immunol       Date:  1990-07       Impact factor: 5.532

7.  Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action.

Authors:  S Hill; K B Williams; J Denekamp
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

8.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

9.  Hyperplasia and growth of the true mesentery in the diabetic rat.

Authors:  K Norrby; S Bergström; P Druvefors
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1983-05

10.  Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kd protein in mouse epidermis.

Authors:  M Gschwendt; W Kittstein; F Marks
Journal:  Carcinogenesis       Date:  1987-02       Impact factor: 4.944

View more
  4 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 2.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

3.  Altered vascular endothelium integrin expression in psoriasis.

Authors:  D Creamer; M Allen; A Sousa; R Poston; J Barker
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

4.  Cyclosporin a disrupts notch signaling and vascular lumen maintenance.

Authors:  Raghav Pandey; Mark A Botros; Benjamin A Nacev; Allan R Albig
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.